Loading data for ACXP — first visit, this takes a few seconds.

提醒

Acurx Pharmaceuticals Inc... (ACXP)

NasdaqCM: ACXP · 即時價格 · USD

1.40

-0.08 (-5.41%)

收盤時： Aug 14, 2026, 6:04 PM

-5.41% (1D)

無可用資料

買價	1.08
市值	6.02M
營收 (ttm)	n/a
淨利（ttm）	-7.5M
貝塔	-2.03
EPS (ttm)	-3.79
本益比（ttm）	n/a
正向 PE	-0.66
P/B (ttm)	0.68
P/S (ttm)	n/a
Earnings Date	Aug 14, 2026

賣價	1.94
成交量	572,673
20 日平均成交量	95,330
打開	1.40
上一頁關閉	1.48
日間範圍	1.31 - 1.44
52 週範圍	1.31 - 8.34
分析師	n/a
目標價	n/a
股利	n/a
Ex-股利日期	n/a

關於ACXP

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-pos...

[閱讀更多]

工業 Biotechnology

部門 Healthcare

IPO 日期 Jun 25, 2021

員工 4

證券交易所 NasdaqCM

股票代號 ACXP

網站 https://www.acurxpharma.com

完整的公司簡介

財務表現

Acurx Pharmaceuticals 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -7.97M，較前期減少 -43.51%。

財務報表

獲利驚喜

Acurx Pharmaceuticals 已於 May 11, 2026 公布季度財報：

營收的 $0 錯過估計 $0, 與 NaN% YoY 成長.

EPS 的 -0.62 超出估計 0.01, 與 71.82% YoY 成長.

下次財報發布

Acurx Pharmaceuticals Inc. 定於發布財報 Aug 14, 2026, 開市前。
分析師預估營收 ... 升級

新聞動態

2 月前 · Zacks

Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why

Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 月前 · Moby

Acurx Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

Moby summary of Acurx Pharmaceuticals, Inc.'s Q1 2026 earnings call

4 月前 · Zacks

Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.

4 月前 · GuruFocus.com

Acurx Pharmaceuticals Inc (ACXP) Q4 2025 Earnings Call Highlights: Financial Growth and ...

Acurx Pharmaceuticals Inc (ACXP) reports improved financial stability and significant progress in clinical trials, despite ongoing challenges.

5 月前 · Zacks

Can Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Acurx Pharmaceuticals (ACXP) points to a 226.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

第 1 頁，共 2 頁

Acurx Pharmaceuticals Inc... (ACXP)